Vanda M. Stepanek

1.2k total citations
21 papers, 885 citations indexed

About

Vanda M. Stepanek is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vanda M. Stepanek has authored 21 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vanda M. Stepanek's work include Colorectal Cancer Treatments and Studies (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Oral Health Pathology and Treatment (5 papers). Vanda M. Stepanek is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Oral Health Pathology and Treatment (5 papers). Vanda M. Stepanek collaborates with scholars based in United States, India and Brazil. Vanda M. Stepanek's co-authors include J. Jack Lee, Filip Jankú, Razelle Kurzrock, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Aung Naing, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu and David S. Hong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Cell Reports.

In The Last Decade

Vanda M. Stepanek

21 papers receiving 866 citations

Peers

Vanda M. Stepanek

PRM

ONCOL

PFM

Alexander C. Klimowicz Canada

Anette Weber Germany

Xiaoyu Tu China

S Dische United Kingdom

Annette Affolter Germany

Bonnie L. King United States

Graham J. Cox United Kingdom

Silvia Varricchio Italy

Raija Ristamäki Finland

Chan-Young Ock South Korea

Alexander C. Klimowicz Canada

Vanda M. Stepanek

821 ×2.2

188 ×0.6

PRM

653 ×2.8

ONCOL

280 ×1.3

136 ×1.0

PFM

Citations per year, relative to Vanda M. Stepanek Vanda M. Stepanek (= 1×) peers Alexander C. Klimowicz

Countries citing papers authored by Vanda M. Stepanek

Since Specialization

Citations

This map shows the geographic impact of Vanda M. Stepanek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanda M. Stepanek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanda M. Stepanek more than expected).

Fields of papers citing papers by Vanda M. Stepanek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanda M. Stepanek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanda M. Stepanek. The network helps show where Vanda M. Stepanek may publish in the future.

Co-authorship network of co-authors of Vanda M. Stepanek

This figure shows the co-authorship network connecting the top 25 collaborators of Vanda M. Stepanek. A scholar is included among the top collaborators of Vanda M. Stepanek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanda M. Stepanek. Vanda M. Stepanek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haraldsdóttir, Sigurdís, Filip Jankú, Ming Poi, et al.. (2018). Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. JCO Precision Oncology. 2(2). 1–19. 1 indexed citations

Haraldsdóttir, Sigurdís, Filip Jankú, Cynthia Timmers, et al.. (2014). 461 A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF mutated advanced malignancies. European Journal of Cancer. 50. 151–151. 1 indexed citations

Jankú, Filip, Cecile Rose T. Vibat, Karena Kosco, et al.. (2014). BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 5(11). 3607–3610. 51 indexed citations

Jankú, Filip, David S. Hong, Siqing Fu, et al.. (2014). Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Reports. 6(2). 377–387. 193 indexed citations

Haraldsdóttir, Sigurdís, Filip Jankú, Cynthia Timmers, et al.. (2014). A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. Journal of Clinical Oncology. 32(15_suppl). TPS2628–TPS2628. 1 indexed citations

Jankú, Filip, Cecile Rose T. Vibat, Gerald S. Falchook, et al.. (2014). Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.. Journal of Clinical Oncology. 32(15_suppl). e22175–e22175. 2 indexed citations

Ganesan, Prasanth, Filip Jankú, Aung Naing, et al.. (2013). Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Molecular Cancer Therapeutics. 12(12). 2857–2863. 38 indexed citations

Jankú, Filip, Gerald S. Falchook, Sarina A. Piha‐Paul, et al.. (2013). Abstract B175: Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR.. Molecular Cancer Therapeutics. 12(11_Supplement). B175–B175. 1 indexed citations

Chae, Young Kwang, David S. Hong, Gerald S. Falchook, et al.. (2013). Abstract 164: PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials .. Cancer Research. 73(8_Supplement). 164–164. 4 indexed citations

10.

Jankú, Filip, Jennifer J. Wheler, Aung Naing, et al.. (2012). PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research. 73(1). 276–284. 218 indexed citations

11.

Jankú, Filip, Aung Naing, Gerald S. Falchook, et al.. (2012). Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.. Journal of Clinical Oncology. 30(4_suppl). 459–459. 3 indexed citations

12.

Jankú, Filip, Jennifer J. Wheler, Aung Naing, et al.. (2012). PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget. 3(12). 1566–1575. 72 indexed citations

13.

Jankú, Filip, Russell Broaddus, David S. Hong, et al.. (2012). PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.. Journal of Clinical Oncology. 30(15_suppl). 10510–10510. 10 indexed citations

14.

Jankú, Filip, Sheng Fu, Sarina A. Piha‐Paul, et al.. (2012). 246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors. European Journal of Cancer. 48. 76–76. 3 indexed citations

15.

Muldoon, Timothy J., Darren Roblyer, Michelle D. Williams, et al.. (2011). Noninvasive imaging of oral neoplasia with a high‐resolution fiber‐optic microendoscope. Head & Neck. 34(3). 305–312. 83 indexed citations

16.

Rahman, Mohammed, Darren Roblyer, Vanda M. Stepanek, et al.. (2010). Evaluation of a low-cost, portable imaging system for early detection of oral cancer. Head & Neck Oncology. 2(1). 10–10. 49 indexed citations

17.

Roblyer, Darren, Cristina Kurachi, Vanda M. Stepanek, et al.. (2010). Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. Journal of Biomedical Optics. 15(6). 66017–66017. 22 indexed citations

18.

Schwarz, Richard A., Wen Gao, Vanda M. Stepanek, et al.. (2010). Prospective evaluation of a portable depth-sensitive optical spectroscopy device to identify oral neoplasia. Biomedical Optics Express. 2(1). 89–89. 9 indexed citations

19.

Roblyer, Darren, Cristina Kurachi, Vanda M. Stepanek, et al.. (2009). Objective Detection and Delineation of Oral Neoplasia Using Autofluorescence Imaging. Cancer Prevention Research. 2(5). 423–431. 122 indexed citations

20.

Stepanek, Vanda M., et al.. (1960). [Our experiences with gridroentgenotherapy of non-neoplastic diseases].. PubMed. 14. 5–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact